Anzeige
Mehr »
Montag, 29.06.2026 - Börsentäglich über 12.000 News
China kontrolliert Seltene Erden - Brasilien könnte die Antwort sein
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: A1137V | ISIN: KYG8807B1068 | Ticker-Symbol: 0TB
Frankfurt
29.06.26 | 08:17
15,300 Euro
+1,32 % +0,200
1-Jahres-Chart
THERAVANCE BIOPHARMA INC Chart 1 Jahr
5-Tage-Chart
THERAVANCE BIOPHARMA INC 5-Tage-Chart
RealtimeGeldBriefZeit
14,60015,50014:39
14,60015,50013:22

Aktuelle News zur THERAVANCE BIOPHARMA Aktie

Aktienalarm. Jetzt kostenlos anmelden!

E-Mail
Aktivieren
  • Alle
  • Pressemitteilungen
  • Empfehlungen
  • Chartanalysen
  • Berichte
ZeitAktuelle Nachrichten
Sprache: Alle DE EN
LeserMedien
12:36Zymeworks to pay $17/share for Theravance Biopharma in $929M deal4
12:10Zymeworks Inc.: Zymeworks to Acquire Theravance Biopharma, Inc.279Acquisition adds YUPELRI (revefenacin), the first and only approved nebulized long-acting muscarinic antagonist (LAMA) for the maintenance treatment of COPD to Zymeworks' portfolioAcquisition...
► Artikel lesen
12:00Theravance Biopharma, Inc.: Theravance Biopharma Enters Into Definitive Agreement To Be Acquired By Zymeworks For $17.00 Per Share In Cash Plus A Contingent Value Right89Theravance Biopharma shareholders to receive $17.00 per share in cash, representing an equity value of approximately $929 million Theravance Biopharma shareholders...
► Artikel lesen
THERAVANCE BIOPHARMA Aktie jetzt für 0€ handeln
DiTheravance Biopharma, Inc. - 8-K, Current Report1
12.06.Theravance Biopharma, Inc. - 8-K, Current Report1
08.05.TBPH Q1 Earnings Beat Amid Strategic Restructuring & Pipeline Hurdle1
07.05.Theravance Biopharma, Inc. Reports First Quarter 2026 Financial Results and Provides Corporate Update377YUPELRI® Collaboration Revenue increased 15% year-over-year1, from $15.4 million to $17.7 million, driven by continued Net Sales growth and improved operating...
► Artikel lesen
07.05.Theravance Biopharma, Inc. - 10-Q, Quarterly Report-
07.05.Theravance Biopharma, Inc. - 8-K, Current Report-
29.04.Summers Value Fund adds TBPH, exits ADMA among Q1 moves4
16.04.Theravance Stock Declines Around 17% in Three Months: Here's Why1
30.03.Theravance Biopharma, Inc. - 8-K, Current Report-
23.03.TD Cowen hebt Kursziel für Theravance Biopharma an - Fokus auf Cashflow nach Restrukturierung3
23.03.TD Cowen raises Theravance Biopharma stock price target on cash flow focus1
23.03.Theravance Biopharma, Inc. - 10-K, Annual Report2
20.03.Theravance's Q4 Earnings and Revenues Miss Estimates2
19.03.Theravance Biopharma stock rating reiterated at Buy by BTIG on revenue beat2
19.03.Theravance Biopharma reports Q4 results2
19.03.Theravance Biopharma, Inc. Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Corporate Update274Organizational restructuring and cost reduction plan following results of the Phase 3 CYPRESS study of ampreloxetine are underway; expected to generate $60 - $70...
► Artikel lesen
19.03.Theravance Biopharma, Inc. - 8-K, Current Report3
Weiter >>
43 Nachrichten in den letzten 12 Monaten
Ich würde die Aktie auf Sicht von 6 Monaten
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
1,1,1